Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for HE-Reference-Cited by-同舟云学术

Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for HE

Published:2015-06-09 Issue:6 Volume:67 Page:880-887
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Bethune Gillian C¹,Veldhuijzen van Zanten Daniel¹,MacIntosh Rebecca F¹,Rayson Daniel²,Younis Tallal²,Thompson Kara³,Barnes Penny J¹

Affiliation:

1. Department of Pathology and Laboratory Medicine; Capital District Health Authority and Dalhousie University; Halifax NS Canada

2. Division of Medical Oncology; Capital District Health Authority and Dalhousie University; Halifax NS Canada

3. Department of Medicine; Research Methods Unit; Capital District Health Authority and Dalhousie University; Halifax NS Canada

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.12723/fullpdf

Reference24 articles.

1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N. Engl. J. Med.,2001

2. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial;Smith;Lancet,2007

3. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31;Perez;J. Clin. Oncol.,2011

4. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 year follow-up of a randomized controlled trial;Gianni;Lancet Oncol.,2011

5. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excisional biopsy in breast cancer: a meta-analysis;Chen;Breast Cancer Res. Treat.,2012

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three-dimensional growth sensitizes breast cancer cells to treatment with ferroptosis-promoting drugs;Cell Death & Disease;2023-09-01

2. Invasive Breast Cancer with HER2 ≥4.0 and;Breast Cancer: Targets and Therapy;2023-08

3. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth;Cell Death & Disease;2022-08-06

4. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study;Annals of Diagnostic Pathology;2022-06

5. Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline;Diagnostic Pathology;2022-01-07